Adaptive Biotechnologies (ADPT) Cash from Operations (2018 - 2026)

Adaptive Biotechnologies has disclosed Cash from Operations across 9 years of filings, most recently posting 9537000.0 for Q1 2026.

• Cash from Operations for Q1 2026 came in at 9537000.0, up 66.52% year-over-year; the trailing twelve-month figure through Mar 2026 was 27039000.0 (up 68.32% YoY), and the FY2025 annual result was 45986000.0, up 51.7% from the prior year.
• Cash from Operations came in at 9537000.0 for Q1 2026 at Adaptive Biotechnologies, down from 2055000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 2055000.0 in Q4 2025 to a low of 64453000.0 in Q1 2022.
• The 5-year median for Cash from Operations is 27065000.0 (2024), against an average of 28882588.24.
• Across the five-year window, Cash from Operations dropped 26.47% in 2022 and surged 116.45% in 2025, its largest moves.
• Adaptive Biotechnologies' Cash from Operations stood at 30019000.0 in 2022, then increased by 10.28% to 26932000.0 in 2023, then soared by 53.62% to 12491000.0 in 2024, then soared by 116.45% to 2055000.0 in 2025, then tumbled by 564.09% to 9537000.0 in 2026.
• The last three Cash from Operations figures came in at 9537000.0 (Q1 2026), 2055000.0 (Q4 2025), and 7127000.0 (Q3 2025), per Business Quant data.